PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
NCT04099134 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000
Last updated 2019-09-25
Summary
PaCaReg is a multicenter registry trial aiming in the assessement of clinical, epidemiological and biological profiles in patients with pancreatic ductal adenocarcinoma
Conditions
- Pancreas Adenocarcinoma
- Pancreas Cancer
Sponsors & Collaborators
-
University of Ulm
lead OTHER
Principal Investigators
-
Thomas Seufferlein, MD · Ulm University Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-10-10
- Primary Completion
- 2028-10-31
- Completion
- 2029-10-31
Countries
- Germany
Study Locations
More Related Trials
-
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
NCT05776342 ·Status: RECRUITING
-
Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
NCT05526443 ·Status: RECRUITING
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Registry for Pancreatic Cancer
NCT03001505 ·Status: WITHDRAWN
-
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
NCT05845801 ·Status: RECRUITING
-
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
NCT05472259 ·Status: RECRUITING ·Phase: PHASE2
-
Management of Symptomatic Advanced Pancreatic Adenocarcinoma
NCT02979483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
NCT05262855 ·Status: COMPLETED ·Phase: PHASE2
-
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
NCT02456051 ·Status: TERMINATED
-
Prospective Monocentric Clinical-biological Database
NCT04136132 ·Status: RECRUITING ·Phase: NA
-
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT05132504 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemo With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
NCT01240304 ·Status: TERMINATED ·Phase: PHASE2
-
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
NCT06807112 ·Status: NOT_YET_RECRUITING
-
68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma
NCT06911021 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Diffusion MRI for Pancreatic Adenocarcinoma
NCT02896946 ·Status: COMPLETED ·Phase: NA
-
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
NCT04835064 ·Status: UNKNOWN ·Phase: PHASE3
-
Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas
NCT01783054 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Pancreas Registry and High Risk Registry
NCT02775461 ·Status: RECRUITING
-
Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients
NCT04888312 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
NCT04926467 ·Status: RECRUITING ·Phase: PHASE2
-
A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma
NCT01983410 ·Status: ACTIVE_NOT_RECRUITING
-
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
NCT01726582 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
NCT03513705 ·Status: COMPLETED ·Phase: NA
-
Pancreatic Cancer Collaborative Registry
NCT00661882 ·Status: COMPLETED
-
Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes
NCT04922515 ·Status: UNKNOWN ·Phase: NA